Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.



home / news releases / RUBY - Rubius Therapeutics falls on initial data for RTX-240 in solid tumors


RUBY - Rubius Therapeutics falls on initial data for RTX-240 in solid tumors

Rubius Therapeutics (RUBY) has reversed early gains in premarket hours after the company reported initial data from its ongoing Phase 1/2 clinical trial of RTX-240 in patients with advanced solid tumors. The stock is trading ~14.1% lower currently.“We believe these data provide clinical validation of our RED PLATFORM® and de-risk our oncology pipeline of Red Cell Therapeutics,” commented Pablo J. Cagnoni, CEO of Rubius.More details to follow….

For further details see:

Rubius Therapeutics falls on initial data for RTX-240 in solid tumors
Stock Information

Company Name: Rubius Therapeutics Inc.
Stock Symbol: RUBY
Market: OTC
Website: rubiustx.com

Menu

RUBY RUBY Quote RUBY Short RUBY News RUBY Articles RUBY Message Board
Get RUBY Alerts

News, Short Squeeze, Breakout and More Instantly...